{
    "nct_id": "NCT06097728",
    "official_title": "A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)",
    "inclusion_criteria": "* Participant must be â‰¥ 18 years at the time of screening\n* Histologically proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid)\n* Advanced unresectable disease that cannot be treated with curative surgery (with or without chemotherapy)\n* WHO/ECOG performance status of 0 or 1 with no deterioration (that is, ECOG PS>1) over the previous 2 weeks prior to day of first dosing\n* Has measurable disease per modified RECIST1.1\n* Has adequate bone marrow reserve and organ function at baseline\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* As judged by the investigator, any condition that would interfere with evaluation of the investigational product or interpretation of participant safety or study results.\n* Active or prior documented autoimmune or inflammatory disorders\n* History of another primary malignancy with exceptions.\n* Uncontrolled intercurrent illness\n* Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human immunodeficiency virus (HIV) infection that is not well controlled\n* Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment\n* Untreated or progressive CNS metastatic disease",
    "miscellaneous_criteria": "Key"
}